Stockscreener 앱 받기
0.00
100.00%
-4.97
시간 외 거래:
4.99
4.99
+
Bluebird Bio Inc 주식(BLUE)의 최신 뉴스
Inside the Future of the Gene Therapy for SCID Market: Forecasts, - openPR.com
Carlyle and SK Capital Complete Acquisition of bluebird bio - orrick.com
Bluebird bio Requests to Dismiss Class Action Filed by Investors - TradingView
Bank of America Corp DE Sells 1,358,195 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
As Gene Therapy Endures ‘Cold Winter,’ FDA Leaders Promise Support - BioSpace
Adrenoleukodystrophy Treatment Market Overview | HSCT, Gene - openPR.com
Nuveen Asset Management LLC Decreases Stock Position in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
BNP Paribas Financial Markets Decreases Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital - MSN
Beta-Thalassemia (B-thal) Market Set to Witness - openPR.com
Sickle Cell Treatment Market 2025 | Advances, Drugs, Therapies & - openPR.com
bluebird bio acquired to scale gene therapy access By Investing.com - Investing.com Canada
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $47,000 Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Deutsche Bank AG Cuts Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Carlyle, SK Capital close deal for bluebird bio, injecting capital for commercial expansion - The Business Journals
Bluebird Bio (BLUE) Acquired by Carlyle and SK Capital Partners | BLUE Stock News - GuruFocus
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus
Carlyle, SK Capital Partners Close Bluebird Bio Acquisition - marketscreener.com
Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital - marketscreener.com
bluebird bio acquired to scale gene therapy access - Investing.com
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital - Business Wire
Carlyle, SK Capital Partners disclose expected closing date of bluebird bio deal - MSN
Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com South Africa
Northern Trust Corp Reduces Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Bluebird Bio (BLUE) Acquisition Nears Completion - GuruFocus
Carlyle, SK Capital, Beacon Set To Close Bluebird Bio Acquisition - Nasdaq
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer - marketscreener.com
Carlyle and SK Capital to acquire bluebird bio - Investing.com India
Carlyle-Led Group Closes Tender Offer for Bluebird Bio - marketscreener.com
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer | BLUE Stock News - GuruFocus
Carlyle's $5 Per Share Bluebird Bio Takeover Set for June 2 Close After Successful Tender - Stock Titan
Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize
Bluebird Bio Beats Investor Suit Over FDA Cancer Warning - Law360
Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads By Investing.com - Investing.com India
Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads - Investing.com
Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's
bluebird bio Reminds Stockholders to Act Now to Tender Shares fo - GuruFocus
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital - BioSpace
Bluebird Beats Investor Lawsuit Over FDA Black Box Warning (1) - Bloomberg Law News
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus
High Noon For bluebird (NASDAQ:BLUE) - Seeking Alpha
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus
Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) Price Target at $44.60 - Defense World
Bluebird Beats Patent Case Over Blood Disease Therapies - Law360
Bluebird Wins Patent Fight Over Two High-Priced Gene Therapies - Bloomberg Law News
Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
1.11%
1.70%
자본화:
|
볼륨(24시간):